Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC

This study is testing whether a combination of camrelizumab (an immunotherapy drug), apatinib (a targeted anti-cancer drug), and FOLFOX chemotherapy works better than camrelizumab plus apatinib alone for people with advanced liver cancer (hepatocellular carcinoma) that has not been treated with systemic therapy before. **You may be eligible if...** - You are 18 or older - You have advanced liver cancer (hepatocellular carcinoma) confirmed by tissue biopsy or imaging - Your cancer is at a stage where surgery or local treatments are no longer suitable, or your cancer has returned after those treatments - You have not received any systemic (whole-body) cancer treatment before - You have at least one measurable tumor on imaging - Your liver is functioning reasonably well (Child-Pugh A or better B) - You are in adequate physical condition (ECOG 0–2) **You may NOT be eligible if...** - You have a different type of liver tumor (e.g., bile duct cancer, mixed cancer types) - You have had a previous or concurrent other cancer in the past 5 years - You have significant fluid build-up in the abdomen (ascites) that cannot be controlled - You have had gastrointestinal bleeding, blood clots, or serious cardiovascular events in the past 6 months - You have active autoimmune disease, serious infections, or HIV - You have received prior anti-PD-1/PD-L1 immunotherapy or apatinib Talk to your doctor to see if this trial is right for you.